in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Stabilitech, Unilife, Genocea and Amarin.
Biologics stabilisation business Stabilitech has appointed Donna Hackett as commercial director. Hackett has 20 years of pharma experience working at ProPharma Partners and BTG.
Ramin Mojdeh has joined Unilife as executive vice president (EVP) and chief operating officer. Mojdeh has 25 years of business leadership from working at Becton Dickinson, GE Healthcare and Boston Scientific.
Genocea Biosciences has promoted Chip Clark to president and CEO. Clark joined Genocea in August 2010 as chief business officer after previously working at Vanda Pharmaceuticals and SmithKline Beecham.
Paul Huff has been named as chief commercial officer at Amarin. Huff has experience of cardiovascular treatments from time working at Reliant Pharmaceuticals and Kos Pharmaceuticals.
Somaxon Pharmaceuticals has hired Robert Cutler as VP, business development. Cutler worked at Biogen Idec for eight years after joining the company from a private legal practice.
Angelos Stergiou has joined Anavex Life Sciences as VP, clinical development and medical affairs. Stergiou has worked with Anavex during his time at Genesis BioPharma.
Aesica has appointed a team to manage its European operations after it acquired three sites from UCB. Simon Clough, who has been at Aesica for three years, is now managing director, formulated products business unit. Katy Linekar has also joined the unit as finance director.
Clough and Linekar will be based at the former-UCB site in Monheim, Germany. Helen Taylor will relocate to the site for three months as part of integration efforts. Similarly, Edd Wood and Janette Waterhouse will temporarily work at Pianezza, Italy and Zwickau, Germany respectively.